Arena Enters Strategic Partnership With Everest

San Diego – December 8, 2017 – Cooley advised Arena Pharmaceuticals on a development and commercialization partnership with Everest Medicines for two product candidates in mainland China, Taiwan, Hong Kong, Macau and South Korea.

The product candidates are ralinepag – for the treatment of pulmonary arterial hypertension – and etrasimod, which is being evaluated for multiple autoimmune diseases, including ulcerative colitis, a form of inflammatory bowel disease. C-Bridge Capital has invested $50 million to fund Everest and has assembled a veteran team to rapidly advance product candidates towards approval and launch.

“We are very pleased to establish a partnership with Everest and C-Bridge Capital around two of our potential best-in-class product candidates,” said Amit D. Munshi, president and CEO of Arena, in a news release. “With new regulations in place in China to expedite approvals, a significant opportunity for ralinepag and etrasimod exists in early synchronization of development programs.”

Arena, which trades on The Nasdaq Global Select Market under the symbol "ARNA," is a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas.

Cooley partner Kay Chandler and special counsel Rena Kaminsky lead the team advising Arena.

Cooley previously advised Arena on its amended agreement with Eisai, a Japanese pharmaceutical company, in early 2017.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Kay Chandler Partner, San Diego
Rena Kaminsky Special Counsel, Palo Alto
James Lu Partner, Shanghai
Bin Wang Associate, Beijing